Dear Investors,
Opus8 and the New York Private Equity Forum (NYPEF) are hosting a private investor briefing with IGC Pharma (NYSE American: IGC), a clinical-stage biotechnology and AI company developing novel therapeutics and predictive intelligence platforms focused on Alzheimer’s disease.
Company Overview
IGC Pharma is a clinical-stage biotechnology and AI company focused on developing innovative solutions for Alzheimer’s disease. The company’s lead therapeutic candidate, IGC-AD1, is currently advancing through a Phase 2 clinical trial targeting agitation in Alzheimer’s disease (AAD), a significant unmet need affecting millions of patients worldwide.
With several anticipated clinical and operational milestones expected in the coming months, IGC Pharma is positioned at the intersection of biotechnology, artificial intelligence, and one of healthcare’s largest and fastest-growing markets.
Key Highlights
• Phase 2 clinical trial nearing completion with multiple anticipated catalysts over the next 4–9 months
• Addressing a significant unmet need in Alzheimer’s disease, a market affecting more than 40 million people globally
• Lead therapeutic candidate designed to improve upon limitations of current treatment options
• AI-powered healthcare platform creating additional growth opportunities beyond therapeutics
• Positioned at the intersection of biotechnology, artificial intelligence, and aging-related healthcare innovation
• Publicly traded with a current valuation significantly below comparable Alzheimer’s-focused biotech companies
